Skip to main content

Table 7 Comparison serum profiles NSCLC vs. cancer-free controls

From: Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling

m/z p-value peptide ID
1777.966 2.18E-06 C3f
1877.9926 9.96E-06  
1545.616 2.49E-05  
1690.9254 2.83E-05 C3f
1865.0022 2.83E-05 C3f
1039.6249 4.67E-05  
1361.7417 5.97E-05  
880.4127 7.62E-05  
1041.6349 0.00010908  
1955.9949 0.00013801  
1015.6267 0.00017407  
1087.5722 0.00017407  
1063.6231 0.00034269  
1092.5826 0.00034269  
2318.2202 0.00034269  
2536.2991 0.00034269  
2105.4972 0.00047573  
1396.5679 0.0005897  
2112.022 0.00072868  
987.5905 0.0013492  
1616.6366 0.0016465 P-FPA
2324.1475 0.0018167 C3 beta
2104.998 0.0022066  
2153.0655 0.0024291  
1450.4893 0.0026719  
2193.1036 0.0032253 C3 beta
898.4169 0.0035395  
3427.8221 0.0035395  
2163.9817 0.0046562  
1670.5947 0.0050941  
2099.1139 0.0072417  
1456.5093 0.0078632  
1418.539 0.0078923  
1630.6679 0.0078923  
2228.0362 0.0078923  
2209.0934 0.0085948 **
3326.6863 0.0085948 Hb alpha
1434.5136 0.01017  
3473.7545 0.01017 Hb alpha
1432.644 0.014108  
1292.4157 0.01933  
1440.5407 0.024299  
2246.1744 0.030331  
2789.0914 0.032609  
3156.6207 0.035032 ITIH4
1276.456 0.037607  
1458.4946 0.040342  
  1. 47 peaks were significantly differential comparing NSCLC patients and healthy volunteers. Ordered by p-value. ** identified by Tempst et al. as high-molecular-weight kininogen [19]. Abbreviations: P-FPA: phospho-fibrinopetide A; C3 beta/f: complement C3 beta/f; Hb alpha: hemoglobin alpha; seAlb: serum albumen; ITIH4: inter-alpha-trypsin inhibitor heavy chain H4